abstract |
The present invention is a method for reducing C-reactive protein in a subject in need of treatment, wherein the subject is at risk of causing a vascular event or the subject has already caused a consequent event, or inflammation The method relates to a sexually transmitted disease or illness. In one embodiment, the vascular event is a cardiovascular event (eg, myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (eg, (cerebral infarction such as transient ischemic attack (TIA)). In yet another embodiment, the vascular event is Peripheral vascular events (eg, intermittent claudication) This method administers a pharmaceutically effective amount of at least one growth hormone promoting compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone promoter is a second growth hormone promoter, an HMG CoA reductase inhibitor, an ACAT inhibitor, a CETP inhibitor, an anti-inflammatory agent, an ACE inhibitor, a beta blocker, a cholesterol absorption inhibitor, nicotine It can be administered with acids, fibric acid derivatives, bile acid scavengers or combinations thereof. |